Piper Jaffray Cos. restated their hold rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research note issued to investors on Tuesday. They currently have a $447.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on REGN. Wells Fargo & Co. reaffirmed a hold rating on shares of Regeneron Pharmaceuticals in a report on Monday, May 23rd. Leerink Swann reaffirmed an outperform rating and set a $530.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 1st. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, June 2nd. Cowen and Company reaffirmed a hold rating on shares of Regeneron Pharmaceuticals in a report on Monday, June 6th. Finally, Vetr lowered shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating and set a $429.64 price objective for the company. in a report on Monday, June 6th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of Hold and a consensus price target of $471.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 408.01 on Tuesday. The stock has a market capitalization of $42.69 billion, a P/E ratio of 63.65 and a beta of 1.24. Regeneron Pharmaceuticals has a 52 week low of $329.09 and a 52 week high of $592.59. The company has a 50 day moving average of $406.94 and a 200 day moving average of $389.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.17. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The business earned $1.21 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period last year, the firm posted $2.89 EPS. The company’s revenue was up 21.4% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals will post $11.00 EPS for the current fiscal year.

In other news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the sale, the director now owns 15,125 shares in the company, valued at $6,428,125. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.40% of the company’s stock.

Large investors have recently modified their holdings of the company. Meiji Yasuda Asset Management Co Ltd. increased its stake in Regeneron Pharmaceuticals by 1.2% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 852 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 10 shares during the period. Wetherby Asset Management Inc. increased its stake in Regeneron Pharmaceuticals by 2.3% in the second quarter. Wetherby Asset Management Inc. now owns 796 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 18 shares during the period. Fagan Associates Inc. increased its stake in Regeneron Pharmaceuticals by 2.5% in the second quarter. Fagan Associates Inc. now owns 820 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 20 shares during the period. American Money Management LLC increased its stake in Regeneron Pharmaceuticals by 3.3% in the second quarter. American Money Management LLC now owns 785 shares of the biopharmaceutical company’s stock worth $274,000 after buying an additional 25 shares during the period. Finally, Cleararc Capital Inc. increased its stake in Regeneron Pharmaceuticals by 1.4% in the first quarter. Cleararc Capital Inc. now owns 1,909 shares of the biopharmaceutical company’s stock worth $688,000 after buying an additional 26 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.